Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.69 |
| ▸ | NR3C2 | P08235 | 15/20 | 0.69 |
| ▸ | PGR | P06401 | 11/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228287 | 0.89 | NR3C1 (0.71) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3213636 | 0.88 | NR3C1 (0.76) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3213435 | 0.84 | NR3C1 (0.64) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3222878 | 0.83 | NR3C1 (0.63) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3222679 | 0.83 | NR3C1 (0.71) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3231312 | 0.82 | NR3C2 (0.62) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3227579 | 0.82 | NR3C1 (0.71) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3226421 | 0.82 | NR3C1 (1.00) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3223209 | 0.81 | NR3C1 (0.69) | NR3C1NR3C2PGRMEN1CYP1A2 | |
| SCHEMBL3223712 | 0.81 | NR3C1 (0.68) | NR3C1NR3C2PGRMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2136811-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-12-30 | — | — | EP | claimed |
| WO-2008124745-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2136811-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008124745-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885NR3C2 3/4885PGR 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.